Business Context and Reporting Period
Company: Medifast, Inc. (NYSE: MED)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Medifast operates a direct-to-consumer health and wellness business through its OPTA VIA brand, utilizing a network of independent coaches to sell weight loss and metabolic health products. In October 2025, the Company announced a strategic transformation to focus on "holistic metabolic health" and introduced "Metabolic Synchronization" science to address metabolic dysfunction.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Revenue | $385.8 million | $602.5 million | (36.0)% |
| Gross Profit | $275.2 million | $444.6 million | (38.1)% |
| Gross Margin | 71.3% | 73.8% | (250 bps) |
| Operating Income (Loss) | $(14.2) million | $2.9 million | (593.8)% |
| Net Income (Loss) | $(18.7) million | $2.1 million | (993.0)% |
| Diluted EPS | $(1.70) | $0.19 | N/A |
| Cash & Equivalents | $89.3 million | $90.9 million | (1.8)% |
| Total Investments | $78.0 million | $71.4 million | 9.2% |
| Working Capital | $158.7 million | $150.2 million | 5.7% |
| Active Earning Coaches (Q4) | 16,100 | 27,100 | (40.6)% |
| Revenue per Coach (Q4) | $4,664 | $4,391 | 6.2% |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by $216.7 million (36.0%) primarily due to a 40.6% reduction in the number of active earning coaches (from 27,100 to 16,100). Management attributes this to challenges in client acquisition driven by the rapid adoption of GLP-1 weight loss medications.
- Profitability Shift: The Company transitioned from a net profit of $2.1 million in 2024 to a net loss of $18.7 million in 2025. Operating loss widened to $14.2 million due to lower gross profit and a loss of leverage on fixed costs.
- Expense Reductions: Selling, General, and Administrative (SG&A) expenses decreased by $152.3 million (34.5%), driven by an $85.1 million reduction in coach compensation and lower marketing spend. However, SG&A as a percentage of revenue increased to 75.0% from 73.3%.
- Tax Provision: The Company recorded a $13.0 million income tax expense in 2025 despite a pre-tax loss, resulting in a negative effective tax rate of 231.1%. This was driven by a $12.1 million valuation allowance on deferred tax assets.
- Investment Activity: The Company sold its entire investment in LifeMD common stock during the second quarter of 2025, realizing a gain that contributed to "Other income."
Guidance, Outlook, and Risks
- Strategic Pivot: Management is shifting focus from "transformation to execution" regarding its metabolic health strategy. The Company plans to launch new product innovations in 2026 incorporating "Metabolic Synchronization" science.
- Coach Network: The Company is investing in the "EDGE" program and "Premier+" auto-ship enhancements to improve coach productivity and retention. The goal is to reverse the downtrend in active coaches.
- Competition: The filing highlights significant competitive pressure from GLP-1 medications, which are perceived as easier solutions by consumers. Management positions its coach-guided lifestyle system as a necessary complement to medication for long-term habit change.
- Risks: Key risks include the inability to successfully implement the strategic transformation, continued decline in the coach network, regulatory scrutiny of direct selling models (FTC), and supply chain disruptions. The Company also faces risks related to AI adoption by competitors.
- Liquidity: The Company maintains strong liquidity with $167.3 million in cash, cash equivalents, and investment securities. Dividends were discontinued in December 2023 to fund growth initiatives.
Investor Verification Checklist
- Coach Retention Trends: Verify if the Q4 2025 coach count of 16,100 represents a stabilization or if the decline continues into 2026, as this is the primary driver of revenue.
- GLP-1 Impact: Assess the effectiveness of the new "GLP-1 Nutrition Support Plan" in capturing market share from users of weight loss medications.
- Valuation Allowance: Review the $12.1 million valuation allowance on deferred tax assets and the Company's projections for future taxable income to determine if this charge is permanent.
- Product Launch Timeline: Confirm the 2026 launch schedule for new "Metabolic Synchronization" products and their expected contribution to revenue.
- Fixed Cost Leverage: Monitor SG&A expenses as a percentage of revenue to ensure the Company can scale costs down further if revenue growth does not materialize.